Releases
Investors Scrutinize Disc Medicine Following FDA Rejection
A 22% plunge in Disc Medicine’s stock price on February 13, 2026, has triggered a formal investigation by the Rosen Law Firm. The firm is evaluating potential securities claims, alleging that the company misled shareholders regarding the viability of its bitopertin drug program before federal regulators intervened.
























